NCT01908894View on ClinicalTrials.gov

Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Diabetes Mellitus
Interventions
DRUG

BIOD-123

DRUG

BIOD-125

DRUG

Humalog

Sponsors

Lead Sponsor

Biodel
All Listed Sponsors
lead

Biodel

INDUSTRY

NCT01908894 - Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration | Biotech Hunter | Biotech Hunter